Peter W. Lange

Peter W. Lange

Auto-generated profile, based on publicly available information

Peter W. Lange

Department of Geriatrics and General Medicine, Werribee Mercy Hospital, Werribee 3030, Australia

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2019 in Journal of Clinical Nursing
Verified
Journal Article
Closed access
PDF file
PLPeter W. Lange
Peter W. Lange
MLMarissa Lamanna
Marissa Lamanna
RWRosie Watson
Rosie Watson
Andrea Britta MaierAndrea Britta Maier
Andrea Britta Maier

1 June 2018 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
ZHZina Hijazi
Zina Hijazi
PLPeter Lange
Peter Lange
RWRosie Watson
Rosie Watson
Andrea Britta MaierAndrea Britta Maier
Andrea Britta Maier

1 January 1995 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
MPMarzia Puccioni-Sohler
Marzia Puccioni-Sohler
PRPeter Rieckmann
Peter Rieckmann
BKBernd Kitze
Bernd Kitze
PLPeter Lange
Peter Lange
MAMeike Albrecht
Meike Albrecht
KFKlaus Felgenhauer
Klaus Felgenhauer

27 January 2020 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
PLPeter W. Lange
Peter W. Lange
DCDaniel Clayton-Chubb
Daniel Clayton-Chubb
RWRosie Watson
Rosie Watson
Andrea Britta MaierAndrea Britta Maier
Andrea Britta Maier

4 March 2024 in Journal of the American Geriatrics Society
Verified
Journal Article
Open access
PLPeter W. Lange
Peter W. Lange
ATAlisa Turbić
Alisa Turbić
CSCheng Hwee Soh
Cheng Hwee Soh
DCDaniel Clayton-Chubb
Daniel Clayton-Chubb
WLWen Kwang Lim
Wen Kwang Lim
Andrea Britta MaierAndrea Britta Maier
Andrea Britta Maier
Background: Delirium is common in older inpatients, causing distress, cognitive decline, and death. Current therapies are unsatisfactory, limited by lack of efficacy and adverse effects. There is an urgent need for effective delirium treatment. Sleep wake cycle is disturbed in delirium; endogenous Melatonin is perturbed, and exogenous Melatonin is a safe and effective medication for sleep disorders. This study aims to determine the effect of oral Melatonin 5 mg immediate release (IR) nightly for five nights on the severity of delirium in older (≥65 years) medical inpatients. Methods: This was a double‐blinded, randomized controlled trial in general internal medicine units of a tertiary teaching hospital. Older inpatients with Confusion Assessment Method positive, hyperactive or mixed delirium within 48 h of admission or onset of in‐hospital delirium were included. The primary outcome was change in delirium severity measured with the Memorial Delirium Assessment Scale (MDAS). A previous pilot trial showed 120 participants randomized 1:1 to Melatonin or Placebo would provide 90% power to demonstrate a 3‐point reduction in the MDAS. Results: One hundred and twenty participants were randomized, 61 to Melatonin 5 mg and 59 to Placebo. The medication was well tolerated. The mean MDAS improvement was 4.9 (SD 7.6) in the Melatonin group and 5.4 (SD 7.2) in the Placebo group, p ‐value 0.42, a non‐significant difference. A post‐hoc analysis showed length of stay (LOS) was shorter in the intervention group (median 9 days [Interquartile Range (IQR) 4, 12] vs. Placebo group 10 [IQR 6, 16] p ‐value = 0.033, Wilcoxon Rank Sum test). Conclusions: This trial does not support the hypothesis that Melatonin reduces the severity of delirium. This may be due to no effect of Melatonin, a smaller effect than anticipated, an effect not captured on a multidimensional delirium assessment scale, or a type II statistical error. Melatonin may improve LOS; this hypothesis should be studied.

30 June 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
DCDaniel Clayton-Chubb
Daniel Clayton-Chubb
WKWilliam Kemp
William Kemp
AMAmmar Majeed
Ammar Majeed
PLPeter W. Lange
Peter W. Lange
JWJessica Wood
Jessica Wood
SRStuart Keith Roberts
Stuart Keith Roberts
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the commonest cause of chronic liver disease worldwide. Its incidence has been increasing rapidly, alongside the growing epidemics of type 2 diabetes mellitus and overweight/obesity. Global population age has also been increasing in parallel, and predictions indicate there will be more than 2 billion persons aged over 65 by the year 2050. The interplay between MASLD and other health conditions of older persons has been a focus of recent research. In this narrative review, we aim to describe its prevalence; clinical and sociodemographic associations; and outcomes for older persons, all of which are of significant importance when considering public health messaging as well as screening and counselling individual older adults.